Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection

American Journal of Medicine

Volumn 113, Issue 3, 2002, Pages 229-232

  Lenert, Leslie A ^a,b,c   Feddersen, Martin ^b   Sturley, Ann ^b   Lee, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; COMPUTER; CONTROLLED STUDY; FEMALE; HEALTH BEHAVIOR; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LIFE EXPECTANCY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RISK ASSESSMENT; VIRUS LOAD; VISUAL ANALOG SCALE;

ADAPTATION, PSYCHOLOGICAL; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; LIPODYSTROPHY; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROBABILITY; PROGNOSIS; QUALITY OF LIFE; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SYNDROME; TREATMENT OUTCOME;

EID: 0037101988     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01156-7     Document Type: Article

References (18)

1. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 337:1997;725-733.
2. Collier A.C., Coombs R.W., Schoenfeld D.A., et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 334:1996;1011-1017.
3. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 2001;Department of Health and Human Services and Henry J. Kaiser Family Foundation, Washington, DC.
4. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med. 132:2000;306-311.
5. Harrington M., Carpenter C.C. Hit HIV-1 hard, but only when necessary. Lancet. 355:2000;2147-2152.
6. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
7. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus a cohort study . Lancet. 353:1999;2093-2099.
8. Mathews W.C., McCutchan J.A., Asch S., et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care. 38:2000;750-762.
9. Collins E., Wagner C., Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 10:2000;546-550.
10. Safrin S., Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. [editorial] AIDS. 13:1999;2493-2505.
11. Saint-Marc T., Partisani M., Poizot-Martin I., et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 13:1999;1659-1667.
12. Thorn K. Lipodystrophy and altered body shape in HIV a protease inhibitor side effect? What do you tell your patient? Case Manager. 10:1999;45-47.
13. Carr A., Cooper D.A. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med. 339:1998;1296.
14. Lenert L.A. iMPACT3 online tools for development of Web sites for the study of patients' preferences and utilities . Overhage J.M., Converging Information, Technology and Health Care. Proceedings of the 2000 AMIA Annual Symposium, Los Angeles, California, 4-8 November 2000:2000;1172 American Medical Informatics Assocation, Bethesda, Maryland.
15. Lenert L.A. The reliability and internal consistency of an Internet capable computer program for measuring utilities. Qual Life Res. 9:2000;811-817.
16. Lenert L.A., Treadwell J.R. Effects on preferences of violations of procedural invariance. Med Decis Making. 19:1999;473-481.
17. Lenert L.A., Cher D.J., Goldstein M.K., et al. The effect of search procedures on utility elicitations. Med Decis Making. 18:1998;76-83.
18. Shapiro M.F., Morton S.C., McCaffrey D.F., et al. Variations in the care of HIV-infected adults in the United States results from the HIV Cost and Services Utilization Study . JAMA. 281:1999;2305-2315.